Online inquiry

IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10219MR)

This product GTTS-WQ10219MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets RHD gene. The antibody can be applied in prevention of feto-maternal allo-immunization in RhD- women research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001127691.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6007
UniProt ID Q02161
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10219MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7269MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ4930MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ3373MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ10853MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ15741MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ1467MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ9544MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA J6M0
GTTS-WQ13210MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-04950615
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW